{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:26:14Z","timestamp":1788780374220,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.healun.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T02:08:42Z","timestamp":1627697322000},"page":"1279-1300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-1315","authenticated-orcid":false,"given":"Maria M.","family":"Crespo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-9123","authenticated-orcid":false,"given":"Tamara","family":"Claridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Domsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8393-2791","authenticated-orcid":false,"given":"Matthew","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-7164","authenticated-orcid":false,"given":"Kevin M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ging","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Hoetzenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-9769","authenticated-orcid":false,"given":"Siddhartha","family":"Kapnadak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Timofte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Verleden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-2488","authenticated-orcid":false,"given":"Dennis","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Porteous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-8838","authenticated-orcid":false,"given":"Jorge","family":"Mallea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Perch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Olivier","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-0155","authenticated-orcid":false,"given":"Jesper","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-9251","authenticated-orcid":false,"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan R.","family":"Glanville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2021.07.013_bib0001","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2288-7-52","article-title":"An exploration of the use of simple statistics to measure consensus and stability in Delphi studies","volume":"7","author":"Holey","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.healun.2021.07.013_bib0002","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/art.40149","article-title":"2017 American College of Rheumatology\/American Association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"69","author":"Goodman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0003","series-title":"Global Guidelines for the Prevention of Surgical Site Infection","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0004","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.healun.2021.07.013_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.foot.2017.01.009","article-title":"The implications of biologic therapy for elective foot and ankle surgery in patients with rheumatoid arthritis","volume":"30","author":"Diaper","year":"2017","journal-title":"The Foot"},{"key":"10.1016\/j.healun.2021.07.013_bib0006","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.semarthrit.2015.01.008","article-title":"Rheumatoid arthritis: Perioperative management of biologics and DMARDs","volume":"44","author":"Goodman","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.healun.2021.07.013_bib0007","series-title":"Xeljanz: Xeljanz, Xeljanz XR (tofacitinib) [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0008","series-title":"Olumiant: Olumiant (baricitinib) [package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0009","series-title":"Rinvoq: Rinvoq (upadacitinib) [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0010","series-title":"Jyseleca: jyseleca (filgotinib) [package insertion]","year":"2020"},{"key":"10.1016\/j.healun.2021.07.013_bib0011","unstructured":"Pharmaceutical and Medical Devices Japan. Review reports: drugs. Report on deliberation results Smyraf. Accessed August 17, 2021. https:\/\/www.pmda.go.jp\/files\/000233074.pdf."},{"key":"10.1016\/j.healun.2021.07.013_bib0012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0014","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.40780","article-title":"Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis","volume":"71","author":"Van Vollenhoven","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12890-018-0605-9","article-title":"Morbidity and mortality related to pneumonia and TRACHEOBRONCHITIS in ICU after lung transplantation","volume":"18","author":"Tanaka","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0016","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.healun.2021.07.013_bib0018","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled Study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0021","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2019","journal-title":"Ann Int Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0022","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomized, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheumat Dise"},{"key":"10.1016\/j.healun.2021.07.013_bib0023","unstructured":"U.S. Food & Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). Accessed February 4, 2021.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis#:~:text=The%20U.S.%20Food%20and%20Drug,another%20type%20of%20medicine%20called and availability\/initial safety trial results. 2021."},{"key":"10.1016\/j.healun.2021.07.013_bib0024","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","article-title":"Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis","volume":"5","author":"Cohen","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0025","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0026","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1097\/TXD.0000000000000819","article-title":"Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: results from a long-term extension trial","volume":"4","author":"Busque","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.healun.2021.07.013_bib0027","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0028","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cca.2011.12.023","article-title":"Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway","volume":"413","author":"Vafadari","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.healun.2021.07.013_bib0029","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.humimm.2016.12.005","article-title":"Janus kinase inhibition for immunosuppression in solid organ transplantation: is there a role in complex immunologic challenges?","volume":"78","author":"Moore","year":"2017","journal-title":"Hum Immunol"},{"key":"10.1016\/j.healun.2021.07.013_bib0030","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.healun.2021.07.013_bib0031","series-title":"Kineret: Kineret (anakinra)[package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0032","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00296-010-1474-6","article-title":"Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever","volume":"32","author":"Alpay","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.healun.2021.07.013_bib0033","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00296-010-1429-y","article-title":"Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra\u2013case report and review","volume":"32","author":"Hennig","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.healun.2021.07.013_bib0034","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.healun.2021.07.013_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ckj\/sft164","article-title":"Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra","volume":"7","author":"Celebi","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.healun.2021.07.013_bib0036","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ndt\/gfn646","article-title":"Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation","volume":"24","author":"Moser","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00342","article-title":"Peri- and postoperative treatment with the interleukin-1 receptor antagonist anakinra is safe in patients undergoing renal transplantation: case series and review of the literature","volume":"8","author":"Mulders-Manders","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.healun.2021.07.013_bib0038","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12881-017-0457-9","article-title":"Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report","volume":"18","author":"Peces","year":"2017","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.healun.2021.07.013_bib0039","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3109\/14397595.2013.854437","article-title":"Long-term efficacy and safety of Anakinra in a patient with liver transplant due to adult onset still's disease","volume":"24","author":"Yilmaz","year":"2014","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.healun.2021.07.013_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jbspin.2012.04.009","article-title":"Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure","volume":"79","author":"Direz","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.healun.2021.07.013_bib0041","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1097\/TP.0000000000001406","article-title":"Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management","volume":"100","author":"Murali","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0042","series-title":"Rituxan (rituximab)[package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0043","first-page":"A1002","article-title":"Rituximab for the treatment of humoral rejection after human lung transplant","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0044","series-title":"Benlysta: Benlysta (belimumab)[package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00007890-201407151-02290","article-title":"Selective depletion of complement-binding anti-HLA antibodies","volume":"98","author":"Kamoun","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0046","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/S0140-6736(18)30984-X","article-title":"Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial","volume":"391","author":"Banham","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2021.07.013_bib0047","series-title":"Orencia: Orencia (abatacept) [package insert]","year":"2017"},{"key":"10.1016\/j.healun.2021.07.013_bib0048","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-009-1307-7","article-title":"Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis","volume":"31","author":"Mishra","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.healun.2021.07.013_bib0049","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.15319","article-title":"Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation","volume":"19","author":"Badell","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0050","series-title":"Actemra: Actemra (toclizumab) [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0051","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Khanna","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0052","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A Phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab)\u00a0+\u00a0intravenous immunoglobulin in difficult to desensitize patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0053","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1097\/TP.0000000000002691","article-title":"Clinical relevance of posttransplant donor specific antibodies (DSAs) in patients receiving desensitization for HLA incompatible kidney transplantation","volume":"103","author":"Vo","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0054","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12882-018-1065-4","article-title":"The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome","volume":"19","author":"Matsunami","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.healun.2021.07.013_bib0056","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/TP.0000000000002895","article-title":"Impact of tocilizumab (Anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection","volume":"104","author":"Shin","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0057","series-title":"Kevzara: Kevzara (sarilumab) [package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0058","first-page":"1175","article-title":"Tumor necrosis factor inhibitors - state of knowledge. Archives of medical science","volume":"10","author":"Lis","year":"2014","journal-title":"AMS"},{"key":"10.1016\/j.healun.2021.07.013_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Exp Opin Drug Safety"},{"key":"10.1016\/j.healun.2021.07.013_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14740338.2016.1238458","article-title":"Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Bonovas","year":"2016","journal-title":"Exp Opin Drug Safety"},{"key":"10.1016\/j.healun.2021.07.013_bib0061","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jbspin.2015.10.019","article-title":"Risk of postoperative infections and the discontinuation of TNF inhibitors in patients with rheumatoid arthritis: A meta-analysis","volume":"83","author":"Clay","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.healun.2021.07.013_bib0062","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/apt.15184","article-title":"Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease","volume":"49","author":"Lin","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0063","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/apt.12159","article-title":"Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with Crohn's disease- a nationwide cohort study","volume":"37","author":"Norgard","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0064","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.crohns.2013.01.019","article-title":"The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis","volume":"7","author":"Rosenfeld","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.healun.2021.07.013_bib0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4240\/wjgs.v8.i3.274","article-title":"Post-operative abdominal complications in Crohn's disease in the biological era: systematic review and meta-analysis","volume":"8","author":"Waterland","year":"2016","journal-title":"World J Gastro Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0066","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series","volume":"50","author":"Altwegg","year":"2018","journal-title":"Digestive Liver Dis"},{"key":"10.1016\/j.healun.2021.07.013_bib0067","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.transproceed.2017.09.069","article-title":"Efficacy and safety of anti\u2013TNF-\u03b1 agents in inflammatory bowel disease after liver transplant: a case series","volume":"50","author":"Olmedo-Mart\u00edn","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2021.07.013_bib0068","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ecco-jcc\/jjx057","article-title":"Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis","volume":"11","author":"Westerouen van Meeteren","year":"2017","journal-title":"J Crohn's colitis"},{"key":"10.1016\/j.healun.2021.07.013_bib0069","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0070","series-title":"Cimzia: Cimzia (certolizumab) [package Insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0071","series-title":"Nucala: Nucala (mepolizumab) [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0072","series-title":"Cosentyx: Cosentyx (secukinumab) [package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0073","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0074","series-title":"Taltz: Taltz (ixekizumab) [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0075","doi-asserted-by":"crossref","first-page":"e12909","DOI":"10.1111\/dth.12909","article-title":"Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection","volume":"32","author":"Lora","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0076","series-title":"Stelara (ustekinumab) [package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0077","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jamadermatol.2018.4118","article-title":"Association of noninfectious pneumonia with ustekinumab use","volume":"155","author":"Brinker","year":"2019","journal-title":"JAMA Dermato"},{"key":"10.1016\/j.healun.2021.07.013_bib0078","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ecco-jcc\/jjv109","article-title":"Ustekinumab is effective and safe in the treatment of Crohn\u2019s disease refractory to anti-TNFalpha in an orthotopic liver transplant patient","volume":"9","author":"Martinez-Montiel","year":"2015","journal-title":"J Crohns Colitis. England;"},{"key":"10.1016\/j.healun.2021.07.013_bib0079","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/ctg.2017.30","article-title":"Impaired esophageal motility and clearance post-lung transplant: risk for chronic allograft failure","volume":"8","author":"Tangaroonsanti","year":"2017","journal-title":"Clin Transl gastroenterol"},{"key":"10.1016\/j.healun.2021.07.013_bib0080","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jtcvs.2004.10.035","article-title":"Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation","volume":"129","author":"D'Ovidio","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0081","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Pradere","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0082","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","article-title":"Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes","volume":"13","author":"Crespo","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.healun.2021.07.013_bib0083","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.athoracsur.2017.09.038","article-title":"Long-term survival in bilateral lung transplantation for scleroderma-related lung disease","volume":"105","author":"Chan","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0084","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","article-title":"Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience","volume":"13","author":"Miele","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.healun.2021.07.013_bib0085","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","article-title":"Outcomes in systemic sclerosis-related lung disease after lung transplantation","volume":"95","author":"Sottile","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2021.07.013_bib0086","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/CCM.0000000000001525","article-title":"Guidelines for the provision and assessment of nutrition support therapy in the adult critically Ill patient: society of critical care medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)","volume":"44","author":"Taylor","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0087","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/0016-5085(95)90231-7","article-title":"American Gastroenterological Association technical review on tube feeding for enteral nutrition","volume":"108","author":"Kirby","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.healun.2021.07.013_bib0088","first-page":"46","article-title":"Aspiration associated with long-term gastric versus jejunal feeding: a critical analysis of the literature","volume":"71","author":"Lazarus","year":"1990","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.healun.2021.07.013_bib0089","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0016-5107(02)70366-0","article-title":"Comparison of direct percutaneous endoscopic jejunostomy and PEG with jejunal extension","volume":"56","author":"Fan","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.healun.2021.07.013_bib0090","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jpedsurg.2006.05.050","article-title":"Optimal enteral feeding in children with gastric dysfunction: surgical jejunostomy vs image-guided gastrojejunal tube placement","volume":"41","author":"Raval","year":"2006","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0091","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-017-0650-z","article-title":"Lung transplantation in patients with systemic sclerosis","volume":"19","author":"Shah","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.healun.2021.07.013_bib0092","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/rheumatology\/kes160","article-title":"Malnutrition in systemic sclerosis","volume":"51","author":"Harrison","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0093","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/0884533613508435","article-title":"The Academy of Nutrition and Dietetics\/the American Society for Parenteral and Enteral Nutrition consensus malnutrition characteristics: application in practice","volume":"28","author":"Malone","year":"2013","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.healun.2021.07.013_bib0094","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis","volume":"108","author":"Camilleri","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.healun.2021.07.013_bib0095","series-title":"Reglan: Reglan (metoclopramide). [package insert]","year":"2017"},{"key":"10.1016\/j.healun.2021.07.013_bib0096","series-title":"Motlilium: Motilium (domperidone) [pacakge insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0097","series-title":"Motegrity: Motegrity (prucalopride) [package insert]","year":"2018"},{"key":"10.1016\/j.healun.2021.07.013_bib0098","series-title":"Propulsid: cisapride [package insert]","year":"2000"},{"key":"10.1016\/j.healun.2021.07.013_bib0099","series-title":"Erythromycin: [package insert]","year":"2013"},{"key":"10.1016\/j.healun.2021.07.013_bib0100","series-title":"Zithromax: azithromycin [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0016-5085(00)70408-2","article-title":"Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects","volume":"118","author":"Lidums","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.healun.2021.07.013_bib0102","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/DDDT.S125743","article-title":"Mirtazapine for symptom control in refractory gastroparesis","volume":"11","author":"Malamood","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.healun.2021.07.013_bib0103","series-title":"Remeron: Mirtazapine [package insert]","year":"2019"},{"key":"10.1016\/j.healun.2021.07.013_bib0104","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.surg.2018.04.043","article-title":"Wisconsin's enterra therapy experience: a multi-institutional review of gastric electrical stimulation for medically refractory gastroparesis","volume":"164","author":"Shada","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.healun.2021.07.013_bib0105","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.healun.2014.08.016","article-title":"Gastroparesis is common after lung transplantation and may be ameliorated by botulinum toxin-A injection of the pylorus","volume":"33","author":"Hooft","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2021.07.013_bib0106","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jtcvs.2019.02.128","article-title":"Foregut function before and after lung transplant","volume":"158","author":"Masuda","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0107","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s11605-011-1607-6","article-title":"Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement","volume":"15","author":"Hibbard","year":"2011","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0108","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.thorsurg.2005.03.001","article-title":"Antireflux surgery in the setting of lung transplantation: strategies for treating gastroesophageal reflux disease in a high-risk population","volume":"15","author":"Hartwig","year":"2005","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.healun.2021.07.013_bib0109","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1442-2050.2008.00828.x","article-title":"Lung transplantation in patients with connective tissue disorders and esophageal dysmotility","volume":"21","author":"Gasper","year":"2008","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.healun.2021.07.013_bib0110","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s11605-008-0674-9","article-title":"Gastroesophageal reflux disease and connective tissue disorders: pathophysiology and implications for treatment","volume":"12","author":"Patti","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0111","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.athoracsur.2007.06.025","article-title":"Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma","volume":"84","author":"Kent","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.healun.2021.07.013_bib0112","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2217\/ijr.10.17","article-title":"Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management","volume":"5","author":"McMahan","year":"2010","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.healun.2021.07.013_bib0113","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.healun.2021.07.013_bib0114","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00296-014-3025-z","article-title":"Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon","volume":"34","author":"Kamata","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.healun.2021.07.013_bib0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0116","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/41.3.324","article-title":"Digital vascular response to topical glyceryl trinitrate, as meaured by laser Doppler imaging, in primary Raynaud's phenomenonand systemic sclerosis","volume":"41","author":"Anderson","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0117","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, paralell-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.healun.2021.07.013_bib0118","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoinmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.healun.2021.07.013_bib0119","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparision of intravenous infusions of iloprost and oral nifedipien in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.healun.2021.07.013_bib0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1191\/1358863x05vm579cr","article-title":"Treprostinil for the treatment of severe digital necrosis in systemic sclerosis","volume":"10","author":"Engle","year":"2005","journal-title":"Vasc Med"},{"key":"10.1016\/j.healun.2021.07.013_bib0121","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitot fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.healun.2021.07.013_bib0122","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.healun.2021.07.013_bib0123","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semarthrit.2016.03.015","article-title":"Thrombotic complications after radial arterial line placement in systemic sclerosis: a case series","volume":"46","author":"Paik","year":"2016","journal-title":"Semin Arthritis Rheum"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249821024347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249821024347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:41:19Z","timestamp":1760949679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249821024347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":123,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1053249821024347"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2021.07.013","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}